Sorafenib induced acral pigmentation: A new entity

Sorafenib is a multikinase inhibitor commonly used for the treatment of advanced renal cell and hepatocellular carcinoma. The commonly reported dermatological adverse effects of Sorafenib include hand-foot syndrome (HFS), alopecia, pruritus, facial and scalp erythema, splinter hemorrhages, keratoaca...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Mrinal Gupta, Heena Gupta, Anish Gupta
Formato:	article
Lenguaje:	EN
Publicado:	Thieme Medical and Scientific Publishers Pvt. Ltd. 2015
Materias:	acral pigmentation hand foot syndrome sorafenib Medicine R
Acceso en línea:	https://doaj.org/article/fd80886f7a3142ab83d6f4136991577e
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:fd80886f7a3142ab83d6f4136991577e
record_format	dspace
spelling	oai:doaj.org-article:fd80886f7a3142ab83d6f4136991577e2021-12-02T16:34:20ZSorafenib induced acral pigmentation: A new entity2231-07702249-446410.4103/2231-0770.154199https://doaj.org/article/fd80886f7a3142ab83d6f4136991577e2015-04-01T00:00:00Zhttp://www.thieme-connect.de/DOI/DOI?10.4103/2231-0770.154199https://doaj.org/toc/2231-0770https://doaj.org/toc/2249-4464Sorafenib is a multikinase inhibitor commonly used for the treatment of advanced renal cell and hepatocellular carcinoma. The commonly reported dermatological adverse effects of Sorafenib include hand-foot syndrome (HFS), alopecia, pruritus, facial and scalp erythema, splinter hemorrhages, keratoacanthomas, squamous cell carcinomas and eruptive melanocytic naevi. We report a case of asymptomatic hyperpigmentation of the palms and soles in a patient receiving Sorafenib therapy for advanced renal cell carcinoma, in the absence of features of classic HFS, which has not been previously reported in the literature.Mrinal GuptaHeena GuptaAnish GuptaThieme Medical and Scientific Publishers Pvt. Ltd.articleacral pigmentationhand foot syndromesorafenibMedicineRENAvicenna Journal of Medicine, Vol 05, Iss 02, Pp 46-48 (2015)
institution	DOAJ
collection	DOAJ
language	EN
topic	acral pigmentation hand foot syndrome sorafenib Medicine R
spellingShingle	acral pigmentation hand foot syndrome sorafenib Medicine R Mrinal Gupta Heena Gupta Anish Gupta Sorafenib induced acral pigmentation: A new entity
description	Sorafenib is a multikinase inhibitor commonly used for the treatment of advanced renal cell and hepatocellular carcinoma. The commonly reported dermatological adverse effects of Sorafenib include hand-foot syndrome (HFS), alopecia, pruritus, facial and scalp erythema, splinter hemorrhages, keratoacanthomas, squamous cell carcinomas and eruptive melanocytic naevi. We report a case of asymptomatic hyperpigmentation of the palms and soles in a patient receiving Sorafenib therapy for advanced renal cell carcinoma, in the absence of features of classic HFS, which has not been previously reported in the literature.
format	article
author	Mrinal Gupta Heena Gupta Anish Gupta
author_facet	Mrinal Gupta Heena Gupta Anish Gupta
author_sort	Mrinal Gupta
title	Sorafenib induced acral pigmentation: A new entity
title_short	Sorafenib induced acral pigmentation: A new entity
title_full	Sorafenib induced acral pigmentation: A new entity
title_fullStr	Sorafenib induced acral pigmentation: A new entity
title_full_unstemmed	Sorafenib induced acral pigmentation: A new entity
title_sort	sorafenib induced acral pigmentation: a new entity
publisher	Thieme Medical and Scientific Publishers Pvt. Ltd.
publishDate	2015
url	https://doaj.org/article/fd80886f7a3142ab83d6f4136991577e
work_keys_str_mv	AT mrinalgupta sorafenibinducedacralpigmentationanewentity AT heenagupta sorafenibinducedacralpigmentationanewentity AT anishgupta sorafenibinducedacralpigmentationanewentity
_version_	1718383790444773376

Sorafenib induced acral pigmentation: A new entity

Ejemplares similares